Artificial intelligence-driven cardiac amyloidosis screening
- PMID: 38519149
- DOI: 10.1016/S2589-7500(24)00024-4
Artificial intelligence-driven cardiac amyloidosis screening
Conflict of interest statement
RJHM has received research and consulting support from Pfizer. JA declares no competing interests.
Comment on
-
Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study.Lancet Digit Health. 2024 Apr;6(4):e251-e260. doi: 10.1016/S2589-7500(23)00265-0. Lancet Digit Health. 2024. PMID: 38519153
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
